Here’s to 20 years of a true partnership in true discovery
Can you believe it’s been 20 years since we introduced the first SPECT/CT system? Incredible. When we set out to help make SPECT/CT the essential clinical tool we believed it could be, we perceived only a glimmer of its potential. Today, we continue to be in awe as we watch you use this technology every day to better diagnose your patients and to further your own clinical research.
To celebrate this true partnership in true discovery, we’re introducing the 800 Series. This new family of five nuclear medicine systems puts into practice everything we’ve learned over the course of 20 years by bringing the latest in SPECT/CT advancements to a wider range of clinical environments. Along with the breakthrough CZT-based NM/CT 870 CZT, the digital-ready NM/CT 870 DR and the SPECT-only NM 830, the 800 Series includes two eight-slice CT hybrids. With NM/CT 850, you'll find a low-dose CT for nuclear medicine hybrid imaging that delivers high specificity for localization and attenuation correction, while NM/CT 860 also provides diagnostic CT capabilities. We strategically paired these two systems with CT technology that makes state-of-the-art CT performance accessible to practices with emerging or more routine hybrid needs.
Leveraging the success of the 600 Series, the 800 Series includes a collection of SPECT enhancements like SwiftScan Planar and SwiftScan SPECT that can increase sensitivity and enable reduction of scan times or injected dose by as much as 25 percent1, without a loss in signal-to-noise ratio. It also includes the all-new SmartConsole. This digital processing platform modernizes nuclear medicine workflow by automating SPECT/CT reconstruction and enabling you to review scans remotely from your own mobile devices.
The 800 Series reflects our continued commitment to helping improve the quality, access and affordability of SPECT/CT, so you can continue in your work to change lives for the better.